As of July 21, 2026, Kyoway BioScience, Inc. exercised 14,251 shares (10.48% of the issued total) of the 23rd stock acquisition rights, resulting in an unexercised remaining of 1,498,400 shares.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4583","jir_company_name":"Kyoway BioScience, Inc.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-07-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4583-20260722-01.pdf","jir_short_summary":"As of July 21, 2026, Kyoway BioScience, Inc. exercised 14,251 shares (10.48% of the issued total) of the 23rd stock acquisition rights, resulting in an unexercised remaining of 1,498,400 shares.","jir_summary":"### Stock Acquisition Rights Exercise Status\nThis report provides a detailed account of the exercise status of the 23rd stock acquisition rights issued in December 2025 during the period from July 1 to 21, 2026. During this period, 14,251 stock acquisition rights were exercised, reaching an exercise ratio of 10.48%. Consequently, the number of issued shares amounted to 1,425,100. Meanwhile, the unexercised remaining stock acquisition rights decreased from 29,235 units at the end of the previous month to 14,984 units, indicating ongoing exercise activity. The exercise price ranged between 66.3 yen and 72.7 yen.\n\n### Impact on Shareholders and Future Outlook\nThe large-scale exercise of stock acquisition rights may lead to dilution of shares, but given the relatively low exercise ratio, the short-term impact on shareholder value is considered limited. Going forward, it will be important to monitor the exercise status while developing management strategies based on capital policy and funding trends. The company is expected to continue efforts toward shareholder returns and enhancing capital efficiency.","jir_financial_highlights":"Number of exercised stock acquisition rights: 14,251 units (Exercise ratio 10.48%)\nRemaining unexercised units: 14,984 units (Decreased from 29,235 units at the end of the previous month)\nNumber of issued shares (July 1 to 21): 1,425,100 shares (Unknown)","jir_category":"","jir_hashtags":"#KyowayBioScience, #StockAcquisitionRights, #JapaneseStocks","jir_key_figures":"Number of exercised stock acquisition rights: 14,251 units (exercise ratio 10.48%)\nRemaining unexercised units: 14,984 units (1,498,400 shares)\nNumber of issued shares (July 1 to 21): 1,425,100 shares","jir_meta_title":"\u3010Kyoway BioScience\u3011Stock Acquisition Rights Exercise Status \uff5c July 2026","jir_meta_description":"Kyoway BioScience reports the exercise status of the 23rd stock acquisition rights as of July 21, 2026. Details include an exercise ratio of 10.48% and 1,425,100 shares issued.","jir_og_title":"\u3010Kyoway BioScience\u3011Stock Acquisition Rights Exercise Status \uff5c July 2026","jir_og_description":"Detailed explanation of Kyoway BioScience's stock acquisition rights exercise status. Provides latest information on exercise ratio of 10.48% and 1,425,100 shares issued.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59315,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-86262","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n